Pritchard K I, Quirt I C, Cowan D H, Osoba D, Kutas G J
Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1123-6.
Ninety-seven patients with metastatic malignant melanoma were treated with DTIC, 850 mg/m2 given in single doses at 3--6 week intervals, either alone or in combination with cyclophosphamide (750 mg/m2) and vincristine (2 mg/m2) (DCV). Eighteen patients (19%) had objective disease regression, with a median response duration of 151 days. There was no difference in response rate, response duration, or survival between the group treated with DTIC alone and the group treated with DCV but there was greater gastrointestinal and hematopoietic toxicity in the DCV group. Tumor regression with this single-dose DTIC regimen is similar to that obtained with 5-day courses of DTIC and toxicity is not increased.
97例转移性恶性黑色素瘤患者接受了达卡巴嗪治疗，剂量为850mg/m²，每3 - 6周单剂量给药，可单独使用或与环磷酰胺（750mg/m²）和长春新碱（2mg/m²）联合使用（DCV方案）。18例患者（19%）出现客观疾病缓解，缓解持续时间中位数为151天。单独使用达卡巴嗪治疗组与DCV治疗组在缓解率、缓解持续时间或生存率方面无差异，但DCV组胃肠道和血液系统毒性更大。这种单剂量达卡巴嗪方案的肿瘤缓解情况与5天疗程的达卡巴嗪相似，且毒性未增加。
